2-(甲氧基亚胺)-4-氧代-戊酸乙酯 | 82874-96-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 2-(甲氧基亚胺)-4-氧代-戊酸乙酯
• 英文名称: ethyl 2-(methoxyimino)-4-oxopentanoate
• 英文别名: ethyl 2-methoxyimino-4-oxopentanoate
• CAS: 82874-96-2
• 化学式: C₈H₁₃NO₄
• 分子量: 187.196
• InChiKey: HDMJBDNQNKWAHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  65
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  2-(甲氧基亚胺)-4-氧代-戊酸乙酯 在 lithium hydroxide 、 草酰氯 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 44.0h， 生成 1-(3-cyanophenyl)-N-[2'-(tert-butylaminosulfonyl) [1,1'-biphenyl]-4-yl]-3-methyl-1H-pyrazole-5-carboxamide
  参考文献：
  名称：

  Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

  摘要：

  Factor Xa (fXa) plays a critical role in the coagulation cascade, serving as the point of convergence of the intrinsic and extrinsic pathways. Together with nonenzymatic cofactor Va and Ca2+ on the phospholipid surface of platelets or endothelial cells, factor Xa forms the prothrombinase complex, which is responsible for the proteolysis of prothrombin to catalytically active thrombin. Thrombin, in turn, catalyzes the cleavage of fibrinogen to fibrin, thus initiating a process that ultimately leads to clot formation. Recently, we reported on a series of isoxazoline and isoxazole monobasic noncovalent inhibitors of factor Xa which show good potency in animal models of thrombosis. In this paper, we wish to report on the optimization of the heterocyclic core, which ultimately led to the discovery of a novel pyrazole SN429 (2b; fXa K-i = 13 pM). We also report on our efforts to improve the oral bioavailability and pharmacokinetic profile of this series while maintaining subnanomolar potency and in vitro selectivity. This was achieved by replacing the highly basic benzamidine P-1 with a less basic benzylamine moiety. Further optimization of the pyrazole core substitution and the biphenyl P-4 culminated in the discovery of DPC423 (17h), a highly potent, selective, and orally active factor Xa inhibitor which was chosen for clinical development.

  DOI：

  10.1021/jm000409z
• 作为产物：
  描述：

  乙酰丙酮酸乙酯 在 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.0h， 生成 2-(甲氧基亚胺)-4-氧代-戊酸乙酯
  参考文献：
  名称：

  [EN] 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
  [FR] 1H-PYRAZOLO [4,3-B] PYRIDINES EN TANT QU'INHIBITEURS DE PDE1

  摘要：

  本发明提供了式(I)的1H-吡唑并[4,3-b]吡啶-7-胺作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。

  公开号：

  WO2018007249A1

文献信息

• MACROCYCLES AS PDE1 INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：US20190185489A1

  公开（公告）日：2019-06-20

  The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

  本发明提供了式(I)的大环化合物作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。
• 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：US20190194189A1

  公开（公告）日：2019-06-27

  The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

  本发明提供了式(I)的1H-吡唑并[4,3-b]吡啶类化合物作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。
• [EN] COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES<br/>[FR] TRAITEMENTS COMBINÉS COMPRENANT L'ADMINISTRATION DE 1H-PYRAZOLO [4,3-B] PYRIDINES
  申请人：H LUNDBECK AS

  公开号：WO2019115567A1

  公开（公告）日：2019-06-20

  The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

  本发明提供了式(I)的1H-吡唑并[4,3-b]吡啶-7-胺作为PDE1抑制剂，以及在治疗神经退行性疾病中有用的第二化合物，以及它们的联合使用作为药物，特别用于治疗神经退行性和/或认知障碍。
• Modulators of STING (Stimulator of Interferon Genes)
  申请人：PFIZER INC.

  公开号：US20210087180A1

  公开（公告）日：2021-03-25

  Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  通式（I）的化合物： 或其药用可接受盐，制备这些化合物的方法，含有这些化合物的组合物，以及这些化合物的用途。
• Design, Synthesis and Discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as Highly Potent Factor Xa Inhibitors
  作者：Zhaozhong Jon Jia、Robert Murry Scarborough、Penglie Zhang、Sherin Halfon、Ann Elizabeth Arfsten、Uma Sinha、Bing-Yan Zhu

  DOI：10.1248/cpb.57.1004

  日期：——

  Based upon the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides reported in our previous communications, we designed and discovered 2-(6-chloro-3-methylsulfonyl)-naphthyl as an optimal factor Xa S1 binding element. Employing a key Diels–Alder reaction of 1,4-dihydro-2,3-benzoxathiin-3-oxide with maleic anhydride and a key Cu(I)-mediated methylsulfonylation, we prepared two biphenyl 1-(2-(6-chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitors with Ki values of 0.065 nM and 0.045 nM respectively, and demonstrated the synergistically enhanced binding interaction in the factor Xa S1 site.

  基于我们之前的通讯报道的双苯并[b,f][1,4]氧氮杂卓-1-(2-萘基)-1H-吡唑-5-羧酰胺类化合物，我们设计并发现了2-(6-氯-3-甲磺酰基)萘基作为优选的因子Xa S1结合元件。通过使用1,4-二氢-2,3-苯并噻嗪-3-氧化物与马来酸酐的关键Diels-Alder反应和关键的Cu(I)介导的甲磺酰化反应，我们制备了两种双苯并[b,f][1,4]氧氮杂卓-1-(2-(6-氯-3-甲磺酰基)萘基)-1H-吡唑-5-羧酰胺，它们作为高效的因子Xa抑制剂，其Ki值分别为0.065 nM和0.045 nM，并展示了在因子Xa S1位点协同增强的结合相互作用。